Acrobiosystems Co Ltd
SZSE:301080

Watchlist Manager
Acrobiosystems Co Ltd Logo
Acrobiosystems Co Ltd
SZSE:301080
Watchlist
Price: 43 CNY -4.04%
Market Cap: 5.1B CNY
Have any thoughts about
Acrobiosystems Co Ltd?
Write Note

Acrobiosystems Co Ltd
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Acrobiosystems Co Ltd
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Acrobiosystems Co Ltd
SZSE:301080
Total Liabilities & Equity
ÂĄ2.8B
CAGR 3-Years
133%
CAGR 5-Years
102%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Liabilities & Equity
ÂĄ41.1B
CAGR 3-Years
4%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Total Liabilities & Equity
ÂĄ5.5B
CAGR 3-Years
13%
CAGR 5-Years
53%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Liabilities & Equity
ÂĄ15.7B
CAGR 3-Years
65%
CAGR 5-Years
54%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Total Liabilities & Equity
ÂĄ32.4B
CAGR 3-Years
7%
CAGR 5-Years
23%
CAGR 10-Years
23%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Liabilities & Equity
ÂĄ54.8B
CAGR 3-Years
26%
CAGR 5-Years
38%
CAGR 10-Years
36%
No Stocks Found

Acrobiosystems Co Ltd
Glance View

Market Cap
5.1B CNY
Industry
Biotechnology

ACROBiosystems Co., Ltd. engages in the development of biomedicine and bio-protein technology. The company is headquartered in Beijing, Beijing and currently employs 397 full-time employees. The company went IPO on 2021-10-18. The firm's main products are recombinant proteins and detection services, as well as kits, antibodies, fillers, culture media and other related products. The firm's main products and services are applied to research and development (R&D) and production links such as early drug discovery and verification, drug screening and optimization, development and optimization of diagnostic reagents, preclinical and clinical trials, drug production process and process control (CMC) of tumors, autoimmune diseases, cardiovascular diseases, infectious diseases and other diseases.

Intrinsic Value
48.56 CNY
Undervaluation 11%
Intrinsic Value
Price

See Also

What is Acrobiosystems Co Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
2.8B CNY

Based on the financial report for Dec 31, 2023, Acrobiosystems Co Ltd's Total Liabilities & Equity amounts to 2.8B CNY.

What is Acrobiosystems Co Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
102%

Over the last year, the Total Liabilities & Equity growth was 3%. The average annual Total Liabilities & Equity growth rates for Acrobiosystems Co Ltd have been 133% over the past three years , 102% over the past five years .

Back to Top